Abstract: The present invention relates to natural extracts as a source of therapeutic compounds for human use, specifically for curing and preventing cancerous and tumorous conditions. More specifically, the present invention relates to extracts, compositions or the extracts and methods to produce the extracts from Deschampsia antarctica for prevention of cancer.

Abstract: This invention describes an agent for cutaneous photoprotection against UVA (I and II) and UVB radiation that contains an aqueous extract obtained from a plant in the Gramineae family from the Antarctic Continent (Deschampsia Antarctica), which presents both antioxidant and dissipation of excess UV radiation properties.

Abstract: This invention describes a new agent for cutaneous photoprotection against UVA (I and II) and UVB radiation that contains an aqueous extract obtained from a plant in the Gramineae family from the Antarctic Continent (Deschampsia Antarctica), which presents both antioxidant and dissipation of excess UV radiation properties.

Abstract: This invention describes antineoplastic compound derived from Deschampsia antarctica plants. The biologically active compounds are further characterized. The described compounds are demonstrated to have a capacity to inhibit cancer cell proliferation.

Abstract: The present disclosure provides a novel antineoplastic extract obtained from Deschampsia antarctica plant. Active components of the antineoplastic extract are also disclosed and a method to prevent proliferation of cancerous or tumorous cells with the extract or with components thereof is disclosed. Furthermore, a method to induce production of active ingredients in in vitro grown plants by submitting the plants to physical or chemical treatements before preparing the antineoplastic extract is disclosed. This disclosure provides compostions of tablets and pellets for treating patients with cancer or for prevention of occurence of cancerous diseases.

Abstract: The present invention relates to pharmaceutical combinations of opioid and non-opioid analgesics in an intimate admixture with caffeine and an analgesic from a series of N-acylated 4-hydroxyphenylamine derivatives, linked via an alkylene bridge to the nitrogen atom of a 1,2-benzisothiazol-3(2H)-one 1,1-dioxide group and methods for their use to alleviate pain in mammals. The analgesic combinations exhibit enhanced analgesic potency and are free from antipyretic activity, do not suppress blood coagulation, and have little hepatotoxic effect.

Abstract: The present invention relates to pharmaceutical combinations of opioid and non-opioid analgesics in an intimate admixture with an analgesic from a series of N-acylated 4-hydroxyphenylamine derivatives, linked via an alkylene bridge to the nitrogen atom of a 1,2-benzisothiazol-3(2H)-one 1,1-dioxide group and methods for their use to alleviate pain in mammals. The analgesic combinations exhibit enhanced analgesic potency, do not suppress blood coagulation, and have little hepatotoxic effect.

Abstract: The present invention relates to pharmaceutical combinations of opioid and non-opioid analgesics in an intimate admixture with caffeine and an analgesic from a series of N-acylated 4-hydroxyphenylamine derivatives, linked via an alkylene bridge to the nitrogen atom of a 1,2-benzisothiazol-3(2H)-one 1,1-dioxide group and methods for their use to alleviate pain in mammals. The analgesic combinations exhibit enhanced analgesic potency and are free from antipyretic activity, do not suppress blood coagulation, and have little hepatotoxic effect.

Abstract: New analgesic compounds, which are prepared by the hydrolysis of N-acylated 4-hydroxyphenylamine derivatives, their synthesis and pharmaceutical compositions containing them are disclosed. These compounds surprisingly possess high analgesic activity with little hepatotoxic effect, making them more useful than conventional non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of chronic pain.

Abstract: The present invention relates to pharmaceutical combinations of opioid and non-opioid analgesics in an intimate admixture with an analgesic from a series of N-acylated 4-hydroxyphenylamine derivatives, linked via an alkylene bridge to the nitrogen atom of a 1,2-benzisothiazol-3(2H)-one 1,1-dioxide group and methods for their use to alleviate pain in mammals. The analgesic combinations exhibit enhanced analgesic potency and are free from antipyretic activity, do not suppress blood coagulation, and have little hepatotoxic effect.

Abstract: We have synthesized a series of new derivatives of (2-azinylamino) quinone, that have the general formula shown below. Several compounds of this new series of derivatives have been shown to be inhibitors of 5-lipoxygenase, with minimal or no effect on cycloxygenase-1 and 2-(COX-1 and COX-2) activity. where: A is N, CH, or, CCl; B is N, CH, CCH3, or Cph; X is H, Cl, Br, or I; Y is H, or CH3; R1 is H, CH3, OCH3, or Ph; and R2 is H, CH3, OCH3, or Ph; or R1—R2 is (CH═CH)2; and R3 is H or CH3.

Abstract: A new series of derivatives of 2,4,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid and their synthesis have been discovered. Surprisingly, by modifying the substituent of the 3-carboxylic acid group, new compounds were produced with high activity as PAF receptor antagonists. These compounds were shown to protect neurons from brain damage that normally occurs in response to stroke and other cerebrovascular diseases. These compounds are also protective against edema generation resulting from traumatic breakdown of the blood-brain barrier. Moreover, these compounds were found to be non-toxic and cytoprotective of cells undergoing oxidative stress that would normally trigger apoptotic cell death; and to have activity as (a) antagonists of an intracellular platelet activating factor (“PAF”)-binding site, (b) inhibitors of PAF- and cytokine-mediated c-aminoterminal jun kinase (JNK) and extracellular regulated kinase (ERK), and (c) transcriptional inhibitors of COX-2 expression.

Abstract: The present invention is concerned with new pyridine double esters of formula (I), their acids, and pharmaceutically acceptable salts. These compounds can be obtained by oxydation of the corresponding 1,4-dihydropyridines, and they are useful as cardioprotective agents in pharmaceutical compositions.

Abstract: The invention relates to new 1,4-dihydropyridine derivatives of the general formula I ##STR1## in which R.sup.1, R.sup.2, R.sup.3 and n have the meaning stated in the patent claims.The compounds of the invention have a vasodilatory effect and are therefore suitable for the treatment of hypertension. Some of the compounds have a vasoconstrictory effect and can therefore be used for the treatment of hypotension.

Abstract: 4-alkyl-1,4-dihydropyridines with activity antagonistic of the PAF-"acether" of formula (I) are described, in which R is a saturated alkyl chain C1-2; R' is a saturated or unsaturated C1-16 lineal, branched or cyclic chain that can be interrupted by an oxygen atom and can also represent a 2-(N-morpholine) ethyl group; n is 2 or 3, X is oxygen, sulphur or SO2; Ar represents an aromatic ring that cannot be phenyl when X=S and n=2. The compounds (I) can be prepared (a) by reaction of (II) with (III) and with (IV); or (b) by reacting (V) with (VI) and (IV); or (c) by reaction of (VII) with (VI). In these formulas the different radicals have the meaning given above.

Abstract: 4-alkyl-1,4-dihyropyridines, with PAF-antagonist activity, of formula (I) wherein R is saturated C.sub.1 -C.sub.4, R' is saturated C.sub.1 -C.sub.6 alkyl which may be interrupted by an oxygen atom, or 2-tetrahydrofurfuryl and R.sup.2 is saturated C.sub.1 -C.sub.4 or phenyl, the compound wherein R is methyl, R' is ethyl and R.sup.2 is phenyl remain excluded, are described.The compounds (I) are prepared by: (a) reaction of (II) with (III); (b) reaction of (IV) with (V); (c) reaction of (VI) with (III) and with (VII); (d) reaction of (VIII) with (V) and with (VII); or (e) reaction of (VIII) with (VI) and with (VII) in the presence of ammonia. The compounds (I) are useful due to their antagonist activity of the platelet activating factor.

Abstract: Novel quaternary ammonium salts of general formula (I) ##STR1## wherein: R is a saturated or unsaturated, linear or branched alkyl radical of C.sub.1 to C.sub.8.R' is a saturated or unsaturated, linear or branched alkyl radical of C.sub.1 to C.sub.12, or a benzyl radical.n is a number equal to 2 or 3.X.sup..theta. is a halogenide anion, such as Cl.sup..theta., Br.sup..theta., I.sup..theta., are used as phase transfer catalysts, in heterogeneous ionic reactions wherein the reagents are in different phase and have different polarity.

Abstract: The present invention refers to new 1,4-dihydropyridines, to their obtention processes and to their use as antithrombotic drugs. Said new 1,4-dihdyropyridines have the following general formula (I) ##STR1## wherein R represents hydrogen or a saturated or unsaturated alkyl group, with a linear or branched chain of 1 to 8 carbon atoms,R.sup.1 represents an alkyl radical with a linear, branched or cyclic, saturated or unsaturated chain of 1 to 12 carbon atoms, which may be interrupted by an oxygen or by a 2-(N-salicylamido)ethyl group,n is a number equal to 1 or 2.These new 1,4-dihydropyridines are obtained by processes based on the Hantzch reaction or on modifications thereof.

Abstract: New acyl derivatives of p-aminophenol and esters of same useful as pharmacologically active ingredients and process for their preparation.

Abstract: This invention provides a process for the preparation of glycol 2-(p-chlorophenoxy)-2-methylpropionate nicotinate, of formula (I): ##STR1## which process is characterized in that 2-(p-chlorophenoxy)-2-methylpropionic acid, of formula (II): ##STR2## is reacted with ethylene oxide in an inert solvent in the presence of a catalyst, to prepare the monoglycol ester of the acid (II), of formula (III): ##STR3## which is in turn reacted with nicotinic acid chloride in an inert solvent and in the presence of a base, to prepare the final product, of formula (I).